AbbVie adds context to CEO’s comments on drug pricing; Pandora makes a play for pharma ad dollars; shortages expected of drugs manufactured in Puerto Rico
Five things for pharma marketers to know: Monday, September 25, 2017
600 patients are eligible for CAR-T therapy; the FDA halts Keytruda combo study for multiple myeloma; the regulator delays decision on Herceptin biosimilar